First Isolation of Human Parechovirus Type 4 in Yamagata, Japan

Tanaka, Shizuka; Matoba, Yohei; Unno, Maki; Ikeda, Tatsuya; Itagaki, Tsutomu; Mizuta, Katsumi

doi:10.7883/yoken.jjid.2017.179

Cited by 5 publications

(5 citation statements)

References 15 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We isolated PeVA1, PeVA3 and PeVA6 strains using a routine microplate method including six cell lines as well as the LLC-MK2-N cell line, which is sensitive to PeVA viruses, in combination with molecular screening for the PeVA genome, and performed a seroepidemiological study using these representative Yamagata PeVA1, PeVA3 and PeVA6 isolates in 2014 [15,17,23]. In 2016, we succeeded in isolating the first PeVA4 strain in Yamagata [24]. Thus, we applied this PeVA4 strain to a seroepidemiological study.…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Mizuta

Komabayashi

Aoki

et al. 2020

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

Introduction. Although new parechovirus A (PeVA) types, including parechovirus A3 (PeVA3) and PeVA4, have been reported in this century, there have not yet been any seroepidemiological studies on PeVA over a period of several decades. Hypothesis/Gap Statement. The authors hypothesize that PeVA3 and PeVA4 emerged recently. Aims. The aim was to clarify changes in the seroprevalence of PeVA1, PeVA3 and PeVA4. Methodology. Neutralizing antibodies (NT Abs) were measured among residents in Yamagata, Japan in 1976, 1983, 1985, 1990, 1999 and 2017. Results. The total NT Ab-positive rate for PeVA1 was between 90.7 and 100 % for all years analysed, with that for PeVA3 increasing from 39.6 % in 1976 to 69.6 % in 2017, and that for PeVA4 decreasing from 93.9 % in 1976 to 49.1 % in 2017. The distribution of NT Ab titres for PeVA1, PeVA3 and PeVA4 among those aged less than 20 years old was as follows: those ≥1 : 32 for PeVA1 were between 68.0–89.2 % for all years analysed; those ≥1 : 32 for PeVA3 was 15.4 % in 1976, 44.3–54.9 % in 1983–1990 and 64.8–68.0 % in 1999–2017; and those ≥1 : 32 for PeVA4 were between 49.1–67.2 % in 1976–1990, 41.3 % in 1999 and 23.8 % in 2017. Conclusions. Our findings in this seroepidemiological study over four decades suggested that PeVA1 has been stably endemic, while PeVA3 appeared around 1970s and has spread since then as an emerging disease, and occasional PeVA4 infections were common in 1970s and 1980s but have been decreasing for several decades in our community.

show abstract

Section: Introductionmentioning

confidence: 99%

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Mizuta

Komabayashi

Aoki

et al. 2020

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another microplate including the LLC‐MK2‐N cell line was further added independently for the isolation of parainfluenza viruses and parechoviruses 17,23 . In 2016, direct molecular screening of the PeV genome from the clinical specimens by a real‐time polymerase chain reaction (PCR) method, which was modified based on the method reported by Nix et al, was also introduced 24,25 . Since then, PeV genome‐positive specimens were inoculated into LLC‐MK2‐N cell lines, and three to five passages were performed as a two‐step virus isolation method to isolate PeV, particularly PeVA3, more efficiently 17 .…”

Section: Methodsmentioning

confidence: 99%

“…17,23 In 2016, direct molecular screening of the PeV genome from the clinical specimens by a real-time polymerase chain reaction (PCR) method, which was modified based on the method reported by Nix et al, was also introduced. 24,25 Since then, PeV genome-positive specimens were inoculated into LLC-MK2-N cell lines, and three to five passages were performed as a two-step virus isolation method to isolate PeV, particularly PeVA3, more efficiently. 17 The clinical characteristics of children who tested positive for PeVA1 and for whom informed consent was obtained (from their guardian) for The National Epidemiological Surveillance of Infectious Diseases, Japan, were obtained from their medical records.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal antigenic and seroepidemiological analyses of parechovirus A1 in Yamagata, Japan

Mizuta

Itagaki

Katsushima³

et al. 2023

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

To investigate the antigenic changes in parechovirus 1 (PeVA1), seroepidemiological analyses were performed against the Harris strain (Harris), isolated in 1956, and PeVA1/Yamagata.JPN/2021-4785, isolated in 2021, using immune sera and 207 and 237 human serum specimens collected in 2021 and 1976, respectively. Although rabbit immune sera showed the highest neutralization antibody (NT-Ab) titers against the immunized viruses at 1:12 800-1:102 400, they were cross-reactive at 1:400-1:800. All 62 Yamagata isolates obtained between 2001 and 2021 (Yamagata strains), belonging to phylogenetic lineage 1B, reacted more strongly (mostly 4-64 times) to antiserum against PeVA1/Yamagata.JPN/2021-4785 than to antiserum against Harris, belonging to phylogenetic lineage 1 A. Human serum specimens obtained in 2021 showed higher NT-Ab titers against PeVA1/Yamagata.JPN/2021-4785, whereas those obtained in 1976 had similar NT-Ab titers against both strains. These findings suggested that Yamagata strains and Harris were antigenically cross-reactive, although there were differences. There are still high NT-Abs titers present against Harris in 2021 in particular, indicating that PeVA1 has been in circulation with high immunity in the population. In conclusion, this study suggested that PeVA1 has been endemically perpetuated with only minor antigenic changes as well as with high immunity over several decades in the community.

show abstract

“…2A); First, we screen the virus genome directly from the nasopharyngeal specimens using genome amplification methods such as RT-PCR and real-time RT-PCR, and then, we inoculate only the genome-positive specimens onto the appropriate cell lines and perform 3-5 passages. For example, after screening, we inoculate the genomepositive specimens onto the LLC-MK2-Niigata (LLC-MK2-N) cell line for the isolation of parechoviruses (PeVs) (23,24), the RD-18S-Niigata (RD-18S-N) cell line for the isolation of Saffold viruses (SAFVs) (25,26), the RD-A cell line for the isolation of EV-D68 and CV-A6, and the HeLa-ACE2-TMPRSS2 cell line for the isolation of human coronavirus 229E (HCoV-229E) ( Table 2) (27). The LLC-MK2-N and RD-18S-N cell lines have better sensitivities for PeVs and SAFVs, respectively, than the LLC-MK2 and RD-18S cell lines that we have used in our laboratory.…”

Section: -3 Two-step Virus Isolationmentioning

confidence: 99%

Longitudinal Epidemiology of Viral Infectious Diseases Combining Virus Isolation, Antigenic Analysis, and Phylogenetic Analysis as Well as Seroepidemiology in Yamagata, Japan, between 1999 and 2018

et al. 2019

Self Cite

View full text Add to dashboard Cite

First Isolation of Human Parechovirus Type 4 in Yamagata, Japan

Cited by 5 publications

References 15 publications

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Longitudinal antigenic and seroepidemiological analyses of parechovirus A1 in Yamagata, Japan

Longitudinal Epidemiology of Viral Infectious Diseases Combining Virus Isolation, Antigenic Analysis, and Phylogenetic Analysis as Well as Seroepidemiology in Yamagata, Japan, between 1999 and 2018

Contact Info

Product

Resources

About